Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.
Journal: Brain communications
Published: December 03, 2024
Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Journal: Nature medicine
Published: October 16, 2023
TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease.
Journal: Nature aging
Published: July 11, 2023
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Journal: Nature medicine
Published: September 01, 2022
Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD.
Journal: Brain imaging and behavior
Published: January 14, 2021
Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss.
Journal: Science translational medicine
Published: September 11, 2019
Comparison of Medical and Consumer Wireless EEG Systems for Use in Clinical Trials.
Journal: Frontiers in human neuroscience
Published: April 27, 2017
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.
Journal: PloS one
Published: November 04, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: March 10, 2016
Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone.
Journal: Toxicology reports
Published: December 26, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026